Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Proportion of Patients With Completion of 4 Cycles of CT + GB
研究概览
简要总结
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. The objective of the study is to determine whether this drug combination is safe for this patient population and to see if it is effective in shrinking cancers, keeping them from growing or helping patients live longer.
详细描述
Patients who consent to this study will receive treatment for four 28 day cycles unless they are unable to continue study treatment due to toxicity or disease progression. Paclitaxel and carboplatin will be given intravenously on day 1 of each cycle and galunisertib in pill form on days 4-17. No medicine will be given on days 17-28 of each cycle. Patients may have the option of continuing treatment with the study drug if they complete the 4 cycles the study requires. Subjects will receive tests and procedures that are part of regular cancer care as well as those required for the purposes of the study. Blood samples will be taken to monitor the level of study drug in the blood. Patients will have the option of allowing blood and tumor samples to be used for future research.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women ≥ 18 years old with a diagnosis of primary, recurrent or progressive uterine, ovarian, fallopian tube or peritoneal carcinosarcoma, for whom treatment with combination paclitaxel and carboplatin is recommended.
- •Written informed consent/assent prior to any study-specific procedures
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Tissue available for translational study (paraffin block or new biopsy) .
- •Adequate bone marrow, renal, and hepatic function as defined per protocol.
- •No disease-modifying therapy, including investigational treatments, within 28 days prior to initiation of study treatment.
- •Ability to swallow tablets
- •For Women of child-bearing potential:Willingness to use a highly effective method of contraception during the study and for 6 months following the last dose of galunisertib. Negative beta human chorionic gonadotropin pregnancy test documented within 7 days prior to initiation of study drug.
- •Patient must have measurable disease before the treatment
排除标准
- •Planned radiotherapy during or after the study chemotherapy prior to disease progression.
- •Receipt of chemotherapy or radiation within 28 days of study treatment
- •Have had a major surgical procedure or a significant traumatic injury within 28 days prior to study treatment; Minor procedures such as biopsy within 7 days prior to study treatment are allowed.
- •Active infection that would preclude receipt of chemotherapy
- •Moderate or severe cardiovascular disease per protocol
- •Active pregnancy or lactation
- •Second primary malignancy for which treatment during the study period would be recommended if this cancer were not also present.
- •Prior malignancy requiring treatment within the last 3 years
- •Use of another investigational product or device within 4 weeks of study entry or during study participation.
研究组 & 干预措施
Paclitaxel/Carboplatin + Galunisertib
Patients will receive the following in every cycle (1 cycle=28days).
- Paclitaxel - 175 mg/m2 over 3 hours via IV on Day 1
- Carboplatin - AUC 6* (or AUC 5*) over 1 hour via IV on Day 1
- Galunisertib - 150mg orally twice a day on Days 4-17
干预措施: Galunisertib (Drug)
Paclitaxel/Carboplatin + Galunisertib
Patients will receive the following in every cycle (1 cycle=28days).
- Paclitaxel - 175 mg/m2 over 3 hours via IV on Day 1
- Carboplatin - AUC 6* (or AUC 5*) over 1 hour via IV on Day 1
- Galunisertib - 150mg orally twice a day on Days 4-17
干预措施: Paclitaxel (Drug)
Paclitaxel/Carboplatin + Galunisertib
Patients will receive the following in every cycle (1 cycle=28days).
- Paclitaxel - 175 mg/m2 over 3 hours via IV on Day 1
- Carboplatin - AUC 6* (or AUC 5*) over 1 hour via IV on Day 1
- Galunisertib - 150mg orally twice a day on Days 4-17
干预措施: Carboplatin (Drug)
结局指标
主要结局
Proportion of Patients With Completion of 4 Cycles of CT + GB
时间窗: 2 years
Completion of 4 cycles of CT + GB- completion of a cycle will be defined as receiving both carboplatin/paclitaxel and taking ≥75% of the doses of GB for the cycle.
次要结局
- Median Progression Free Survival (Months)(through study completion, an average of 3 years)
- Median Overall Survival (Months)(through study completion, an average of 3 years)
- Objective Response(within three years of study entry)